220 related articles for article (PubMed ID: 34190436)
21. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
22. Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.
Macleod LC; Yabes JG; Fam MM; Bandari J; Yu M; Maganty A; Furlan A; Filson CP; Davies BJ; Jacobs BL
Eur Urol Focus; 2020 Mar; 6(2):242-248. PubMed ID: 31031042
[TBL] [Abstract][Full Text] [Related]
23. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.
Orczyk C; Barratt D; Brew-Graves C; Peng Hu Y; Freeman A; McCartan N; Potyka I; Ramachandran N; Rodell R; Williams NR; Emberton M; Ahmed HU
J Urol; 2021 Apr; 205(4):1090-1099. PubMed ID: 33315505
[TBL] [Abstract][Full Text] [Related]
24. Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.
Ullrich T; Arsov C; Quentin M; Mones F; Westphalen AC; Mally D; Hiester A; Albers P; Antoch G; Schimmöller L
Eur Radiol; 2020 Nov; 30(11):6042-6051. PubMed ID: 32591887
[TBL] [Abstract][Full Text] [Related]
25. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
[TBL] [Abstract][Full Text] [Related]
26. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
Stavrinides V; Giganti F; Trock B; Punwani S; Allen C; Kirkham A; Freeman A; Haider A; Ball R; McCartan N; Whitaker H; Orczyk C; Emberton M; Moore CM
Eur Urol; 2020 Sep; 78(3):443-451. PubMed ID: 32360049
[TBL] [Abstract][Full Text] [Related]
27. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
28. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
29. Oncological Outcomes in Men With Favorable Intermediate Risk Prostate Cancer Enrolled in Active Surveillance.
Pepe P; Pepe L; Pennisi M; Fraggetta F
In Vivo; 2024; 38(3):1300-1305. PubMed ID: 38688647
[TBL] [Abstract][Full Text] [Related]
30. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
31. The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy.
Perrin A; Venderink W; Patak MA; Möckel C; Fehr JL; Jichlinski P; Porcellini B; Lucca I; Futterer J; Valerio M
Urol Oncol; 2021 May; 39(5):297.e9-297.e16. PubMed ID: 33341358
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
[TBL] [Abstract][Full Text] [Related]
33. Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
Rompré-Brodeur A; Marcq G; Tholomier C; Fugaru I; Loutochin O; Anidjar M; Bladou F
J Urol; 2021 Nov; 206(5):1177-1183. PubMed ID: 34251879
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
[TBL] [Abstract][Full Text] [Related]
35. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
36. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
37. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP
BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635
[TBL] [Abstract][Full Text] [Related]
38. Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance.
Mamawala MK; Meyer AR; Landis PK; Macura KJ; Epstein JI; Partin AW; Carter BH; Gorin MA
BJU Int; 2020 Jun; 125(6):861-866. PubMed ID: 32039537
[TBL] [Abstract][Full Text] [Related]
39. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
[TBL] [Abstract][Full Text] [Related]
40. Detection rate for significant cancer at confirmatory biopsy in men enrolled in Active Surveillance protocol: 20 cores vs 30 cores vs MRI/TRUS fusion prostate biopsy.
Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Barbera M; Panella P; Pennisi M; Morgia G
Arch Ital Urol Androl; 2016 Dec; 88(4):300-303. PubMed ID: 28073197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
